Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2006-10-17
2006-10-17
Nolan, Patrick J. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
Reexamination Certificate
active
07122336
ABSTRACT:
This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated with an autoantigen response to hTM in affected tissue.
REFERENCES:
patent: 5869048 (1999-02-01), Das
patent: 6605276 (2003-08-01), Das
patent: WO 96/35449 (1996-11-01), None
patent: WO 99/48508 (1999-09-01), None
Alarcon-Segovia, et al., “Broken dogma: penetration of autoantibodies into living cells,” Immunol. Today, vol. 17, No. 4, (Apr. 1996), pp. 163-164.
Austin, et al., “The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients,” The Journal of Investigative Dermatology, vol. 113, No. 5, (Nov. 1999), pp. 752-759.
Bhagat, et al., “A Shared and Unique Peptide in the Human Colon, Eye, and Joint Detected by a Monoclonal Antibody,” Gastroenterology, vol. 107, (1994), pp. 103-108.
Biancone, et al., “Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives,” Clin Exp Immunol., vol. 113, (1998), pp. 198-205.
Biancone, et al., “Production of Immunoglobulin G and G1 Antibodies to Cytoskeletal Protein by Lamina Propria Cells in Ulcerative Colitis,” Gastroenterology, vol. 109, (1995), pp. 3-12.
Brandtzaeg, “Autoimmunity and ulcerative colitis: Can two enigmas make sense together?,” Gastroenterology, vol. 109, (1995), pp. 307-312.
Brion, et al., “Regulated and constitutive secretion: Differential effects of protein synthesis arrest on transport of glycosaminoglycan chains to the two secretory pathways,” J. Biol. Chem., vol. 267, (Jan. 1992), pp. 1477-1483.
Coligan, “Isolation and analysis of proteins,” Current Protocols in immunology, vol. 2, Ch. 8, (1994), pp. 8.0.5-8.0.7.
Coulier, et al., “Mechanism of activation of humantrkoncogene,” Mol. Cell. Biol., vol. 9, No. 1, (Jan. 1989), pp. 15-23.
D'Argenio, et al., “Recombinant Factor XIII Replacement Therapy in Experimental Colitis in Rats,” abstrace, Gastroenterology: Immunology, Microbiology, and Inflammatory Disorders, vol. 112, No. 4, (Apr. 1997), p. A955.
Das, et al., “A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody,” Gastroenterology, vol. 98, (1990), pp. 464-469.
Das, et al., “Autoimmunity to Cytoskeletal Protein Tropomyosin: A Clue to the Pathogenetic Mechanism for Ulcerative Colitis,” The Journal of Immunology, vol. 150, No. 6, (Mar. 15, 1993), pp. 2487-2493.
Das, et al., “Cell surface display of tropomyosin (TM), a putative autoantigen in ulcerative colitis (UC), is dependent on a colon epithelial-specific glycoprotein (CEP),” abstract, Gastroenterology: Immunology, Microbiology, and Inflammatory Disorders, vol. 112, (Apr. 1997), p. A955.
Das, et al., “The Production and Characterization of Monoclonal Antibodies to a Human Colonic Antigen Associated with Ulcerative Colitis: Cellular Localization of the Antigen by Using the Monoclonal Antibody,” The Journal of Immunology, vol. 139, No. 1, (1987), pp. 77-84.
Das, et al., “Relationship of Extraintestinal Involvements in Inflammatory Bowel Disease: New Insights into Autoimmune Pathogensis,” Digestive Diseases and Sciences, vol. 44, No. 1, (1999), pp. 1-13.
Derventzi, et al., “Phorbol ester-induced reorganiztion the cytoskeleton in human fibroblasts during aging in vitro,” Biochem. Biophys. Res. Commun., vol. 182, No. 3, (Feb. 14, 1992), pp. 1423-1428.
Dohlman, et al., “Long charge-rich alpha-helices in systemic autoantigens,” Biochem. Biophys. Res. Commun., vol. 195, No. 2, (Sep. 15, 1993), pp. 686-696.
Geng, et al., “Tropomyosin Isoforms in Intestinal Mucosa: Production of Autoantibodies of Tropomyosin Isoforma in Ulcerative Colitis,” Gastroenterology, vol. 114, (1998), pp. 912-922.
Gimona, et al., “Specificity of dimer formation in tropomyosins: Influence of alternatively spliced exons on homodimer and heterodimer assembly,” Proc. Natl. Acad. Sci, USA, vol. 92, (Oct. 1995), pp. 9775-9780.
Halstensen, “Epithelial Deposition of Immunoglobulin G1 and Activated Complement (C3b and Terminal Complement Complex) in Ulcerative Colitis,” Gastroenterology, vol. 98, 91990), pp. 1264-1271.
Halstensen, “Surface epithelium-related activation of complement differs in Crohn's disease and ulcerative colitis,” Gut, vol. 33, (1992), pp. 902-908.
Hamilton, et al., Autoimmunity in ulcerative colitis:Tropomyosin is not the major antigenic determinant of the Das monoclonal antibody, 7E12H12., Clin Exp Immunol, vol. 99, (1995), pp. 404-411.
Hassan, et al., “Expression of a unique protein on colon cancer cells that reacts with a novel monoclonal antibody and ulcerative colitis serum,” Clin Exp Immunol, vol. 100, (1995), pp. 457-462.
Holmes, “Preparation of Cells and reagents for flow cytometry,” Current Protocols in Immunology, Unit 5.3, (1994), pp. 5.3.1-5.3.23.
Hussain, et al., “Leprosy patients with lepromatous disease recognize cross-reactive T cell epitope in theMycobacterium laprae10-kD antigen,” Clin Exp Immunol, vol. 114, (1998), pp. 204-209.
Kesari, et al., “Externalization of tropomyosin isoform 5 in colon epithelial cells,” Clin Exp Immunol, vol. 118, (1999), pp. 219-227.
Kesari, et al., “Rejuvenated expression of H-2Kbin RMS-S cells does not affect alloreactive T cell- or natur cell-mediated lysis,” Immunol. Letts, vol. 38, (1992), pp. 77-83.
Koren, et al., “Autoantibodies to the ribosomal P Proteins React with a Plasma Membrane-related Target on Human Cells,” J. Clin. Invest., vol. 89, (1992), pp. 1236-1241.
Kuchler, et al., “Membrane translocation of proteins without hydrophobic signal peptide,” Curr. Opinion Cell. Biol., vol. 2, (1990), pp. 617-624.
Lees-Miller, et al., “The molecular basis for tropomyosin isoform diversity,” BioEssays, vol. 13, No. 9, (Sep. 1991), pp. 429-437.
Liao, et al., “Antibody-mediated Autoimmune Myocarditis Depends on Genetically Determined Target Organ Sensitivity,” J. Exp. Med., vol. 181, (Mar. 1995), pp. 1123-1131.
Lin, “Differential localization of tropomyosin isoforms in cultured non-muscle cells,” J. Cell.Biol., vol. 107, (Aug. 1988), pp. 563-572.
Lin, et al., “Monoclonal antibodies against chicken tropomyosin isoforms: Production, characterization and application,” Hybridoma, vol. 4, No. 3, (1985), pp. 223-242.
Lin, et al., “Tropomyosin Isoforms in Nonmuscle Cells,” International Review of Cytology, vol. 170, (1997), pp. 1-37.
Marks, “Co-Expression of Human Tropomyosin Isoform 5 and a Novel Colon Epithelial Protein (CEP) in the Colon Epithelium and Extracolonic Organs Commonly Involved in Ulcerative Colitis,” No. G4228.
Mayer, et al., “Evidence for function of Ia molecules on gut epithelial cells in man,” J. Exp. Med., vol. 166, (Nov. 1987), pp. 1471-1483.
McCool, et al., “Regulated and unregulated pathways for MUC2 mucin secretion in human colonic LS180 adenocarcinoma cells are distinct,” Biochem J., vol. 312, (1995), pp. 125-133.
Mignatti, et al., “Release of basic fibroblast growth factor, an angiogenetic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism,” J. Cell. Biochem., vol. 47, (1991), pp. 201-207.
Mion, et al., “Risk of Graft HCV
Licata & Tyrrell P.C.
Nolan Patrick J.
University of Medicine & Dentistry of New Jersey
LandOfFree
Therapeutic and diagnostic methods for ulcerative colitis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic methods for ulcerative colitis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic methods for ulcerative colitis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3713033